UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 147

Sortiert nach

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.475-484

2012

Volltextzugriff (PDF)

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

Cancer discovery, 2013-04, Vol.3 (4), p.430-443

2013

Volltextzugriff (PDF)

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non―Small Cell Lung Cancer

Clinical cancer research, 2012-09, Vol.18 (18), p.4973-4985

2012

Volltextzugriff (PDF)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Investigational new drugs, 2014-08, Vol.32 (4), p.577-586

2014

Volltextzugriff (PDF)

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

Molecular cancer research, 2014-07, Vol.12 (7), p.1042-1054

2014

Volltextzugriff (PDF)

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

Investigational new drugs, 2014-02, Vol.32 (1), p.14-24

2014

Volltextzugriff (PDF)

Development of 17-Allylamino-17-Demethoxygeldanamycin Hydroquinone Hydrochloride (IPI-504), an Anti-Cancer Agent Directed against Hsp90

Proceedings of the National Academy of Sciences - PNAS, 2006-11, Vol.103 (46), p.17408-17413

2006

Volltextzugriff (PDF)

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis

Molecular cancer research, 2014-05, Vol.12 (5), p.703-713

2014

Volltextzugriff (PDF)

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling

PloS one, 2011-04, Vol.6 (4), p.e18552

2011

Volltextzugriff (PDF)

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

International journal of oncology, 2013-01, Vol.42 (1), p.35-43

2013

Volltextzugriff (PDF)

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

Blood, 2010-11, Vol.116 (22), p.4591-4599

2010

Volltextzugriff (PDF)

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors

The Journal of pharmacology and experimental therapeutics, 2012-11, Vol.343 (2), p.529

2012

Volltextzugriff (PDF)

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.353-363

2014

Volltextzugriff (PDF)

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib

Molecular cancer therapeutics, 2012-12, Vol.11 (12), p.2633-2643

2012

Volltextzugriff (PDF)

Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

Clinical cancer research, 2014-01, Vol.20 (2), p.413-424

2014

Volltextzugriff (PDF)

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2422-2432

2015

Volltextzugriff (PDF)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

Investigational new drugs, 2012-12, Vol.30 (6), p.2201-2209

2012

Volltextzugriff (PDF)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Targeted oncology, 2015-06, Vol.10 (2), p.235-245

2015

Volltextzugriff (PDF)

Abstract 5108: The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5108-5108

2014

Volltextzugriff (PDF)

Abstract 1038: Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1038-1038

2013

Volltextzugriff (PDF)

Abstract 5601: Overcoming acquired resistance to BRAF inhibitors in melanoma with the HSP90 inhibitor ganetespib

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5601-5601

2012

Volltextzugriff (PDF)

Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib

Clinical cancer research, 2012-02, Vol.18 (3_Supplement), p.B1-B1

2012

Volltextzugriff (PDF)

Abstract 4409: STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4409-4409

2015

Volltextzugriff (PDF)

Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C130-C130

2013

Volltextzugriff (PDF)

Abstract 2677: Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2677-2677

2011

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(48)
Humans
(38)
Female
(26)
Technology
(26)
Animals
(23)
Mice
(18)
Oncology
(18)
Biological And Medical Sciences
(16)
Physical Sciences
(16)
Cell Line, Tumor
(15)
Hsp90 Heat-Shock Proteins - Antagonists & Inhibitors
(15)
Xenograft Model Antitumor Assays
(15)
Male
(14)
Triazoles - Pharmacology
(13)
Engineering
(12)
Medical Sciences
(12)
Mice, Scid
(12)
Hsp90 Heat-Shock Proteins - Metabolism
(11)
Science & Technology - Other Topics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non―Small Cell Lung Cancer

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

Development of 17-Allylamino-17-Demethoxygeldanamycin Hydroquinone Hydrochloride (IPI-504), an Anti-Cancer Agent Directed against Hsp90

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib

Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Abstract 5108: The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models

Abstract 1038: Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis

Abstract 5601: Overcoming acquired resistance to BRAF inhibitors in melanoma with the HSP90 inhibitor ganetespib

Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib

Abstract 4409: STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors

Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions

Abstract 2677: Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy

Suchergebnisse filtern